Oxford Biomedica Regulatory News (OXB)

7 Feb 2008 07:00

Oxford Biomedica PLC07 February 2008 For Immediate Release 7 FEBRUARY 2008 OXFORD BIOMEDICA: NOTICE OF FY2007 PRELIMINARY RESULTS AND WEBCAST MONDAY 10 MARCH 2008 Oxford, UK - 7 February 2008: Oxford BioMedica (LSE: OXB), a leading genetherapy company, announces that it will be releasing its preliminary results forthe twelve months ended 31 December 2007 on Monday, 10 March 2008. Analyst meeting: An analyst briefing will be held at 10:30 am on 10 March at theoffices of Buchanan Communications, 45 Moorfields, London EC2. Web cast: Simultaneously to the analyst briefing at 10.30 am, there will be alive audio web cast of the results presentation. To connect to the web castfacility, please go to the Company's website: http://www.citycomments.co.ukapproximately 10 minutes (10.20 am) before the start of the briefing. This willalso be available for replay shortly after the presentation. -Ends- For further information, please contact:Oxford BioMedica plc: Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000JPMorgan Cazenove Limited: James Mitford/ Gina Gibson Tel: +44 (0)20 7588 2828City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Tel: +44 (0)20 7466 5000Buchanan CommunicationsScientific/Trade Press Enquiries: Gemma Price/ Holly Griffiths/ Katja Stout Tel: +44 (0)20 7457 2020 College Hill Life SciencesUS Enquiries: Thomas Fechtner Tel: (646) 378 2900 The Trout Group LLC Notes to editors 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising incancer immunotherapy and gene-based therapies. The Company was established in1995, as a spin-out from Oxford University, and is listed on the London StockExchange. The Company has a platform of gene delivery technologies, which are based onhighly engineered viral systems. Oxford BioMedica also has in-house clinical,regulatory and manufacturing know-how. The lead product candidate is TroVax(R),an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventisfor global development and commercialisation. TroVax is in Phase IIIdevelopment. Oxford BioMedica has three other products in clinical development,including ProSavin(R), a novel gene-based treatment for Parkinson's disease, ina Phase I/II trial. The Company is underpinned by over 80 patent families, whichrepresent one of the broadest patent estates in the field. The Company has astaff of approximately 85. Oxford BioMedica has collaborations withsanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licenseesinclude Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock Exchange